GlobeNewswire

Karolinska Development publishes Interim Report (January - September 2017) and reports a positive result for the third quarter

Dela

STOCKHOLM - October 31, 2017. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report for January - September 2017. This is the first time since 2014, when Karolinska Development implemented its new strategy, that the company reports a positive quarterly result. The company will host a conference call and an online presentation on October 31, at 2 pm CET - details below. The full report is available on the Company's website.

"It is gratifying that Karolinska Development is starting to see the effects of the strategy shift implemented in 2014. We have posted a positive quarterly result and our portfolio companies are well-positioned to exploit the phase II results that are expected to become available in 2018. The past quarter has seen the value of Karolinska Development's portfolio increase by SEK 229 million, primarily due to the positive results of Umecrine Cognition's phase Ib study and the stock market listing of Xspray Pharma", says Viktor Drvota, CEO, Karolinska Development.

Third Quarter Highlights 2017

  • Karolinska Development posted a positive quarterly result for the first time since the company's strategy shift in 2014.
  • Karolinska Development reports an increase in the value of its holdings in Umecrine Cognition as a result of the company's positive phase Ib-data (October 2017).
  • Umecrine Cognition presented positive phase Ib data for its GR3027 candidate drug, which is being developed for the treatment of hepatic encephalopathy (September 2017).
  • BioArctic announced that it intends to float the company's class B shares on the NASDAQ First North Stockholm exchange (September 2017).
  • Xspray Pharma AB was listed on the NASDAQ First North exchange in Stockholm. When Karolinska Development sold its Xspray holding to new owners in September 2015, an earn-out agreement ensured that it would, in conjunction with a stock market listing, be entitled to receive a holding of 3.74% of the number of shares after the flotation. Based on the share price on 30 September 2017, the value of these shares and the shares owned indirectly via KCIF Co-Investment Fund KB corresponds to SEK 16.2 million, and the value of Karolinska Development's portfolio holdings has, therefore, increased by an equivalent amount (September 2017). 
  • Aprea Therapeutics enrolled the first patient in a phase Ib/II study of the APR-246 candidate drug for patients with platinum-resistant, high-grade serous ovarian cancer (HGSOC) (August 2017).
  • Karolinska Development appointed Fredrik Järrsten to the position of CFO. Fredrik Järrsten will take up his new position in late 2017, succeeding Christian Tange who, after four years at Karolinska Development, is leaving the company to pursue other opportunities. Tange will, however, remain with the company for a period of time after Järrsten takes over as CFO, in order to ensure an orderly handover (August 2017). 

Significant events after the end of Q3 2017

  • Aprea Therapeutics received the last tranche of SEK 188 million in a financing round of totally SEK 437 million from 2016. Aprea also announced the enrollment of the first patient in a phase Ib/II study in esophageal cancer (October 2017).
  • Umecrine Cognition announced that it had secured SEK 20 million in financing for an exploratory, phase IIa study of the company's candidate drug, GR3027, in an additional therapeutic indication area, namely idiopathic hypersomnia (October 2017).
  • BioArctic was listed on the NASDAQ First North exchange. Karolinska Development's holding are valued at SEK 48 million, based on the offering price on 12 October, corresponding to a sum that is 80 times the investment (October 2017).

  • Karolinska Development and KCIF Co-Investment Fund KB announced the divestment of their holdings in Xspray Pharma AB. The transaction generated SEK 13.3 million to Karolinska Development (October 2017).

Financial update

  • Karolinska Development posted a positive quarterly result for the first time since the company's strategy shift in 2014. The net profit totalled SEK 194.1 million (net loss of SEK 17.9 million in Q3 2016), and the earnings per share were SEK 3.0 (SEK -0.3 in Q3 2016).
  • The result of change in portfolio fair value amounted to SEK 212.2 million. The increase was primarily due to the increase in the valuation of the Umecrine Cognition holding due to the positive results from the phase Ib study presented during the quarter, and to the flotation of Xspray Pharma.
  • The total fair value of the portfolio was SEK 674.0 million at the end of September 2017, an increase from SEK 445.0 million at the end of June 2017.
  • Net sales totalled SEK 0.5 million during the third quarter 2017 (SEK 0.4 million in Q3 2016). 
  • Karolinska Development invested a total of SEK 17.1 million in its portfolio companies during the third quarter. Third quarter investments in the portfolio companies by Karolinska Development and other specialised life sciences investors totalled SEK 21.4 million. 
  • Cash and cash equivalents decreased by SEK 23.7 million during the third quarter, totalling SEK 165.4 million on 30 September 2017.
  • The Parent Company's equity at the end of September 2017 was SEK 235.1 million.

Conference Call and Webbcast

The Company will host a conference call on October 31, 2017 at 2 pm CET. Please dial in at one of the following numbers a few minutes before the start of the conference call:

From Sweden: +46 (0) 8 505 564 74
From the US: +1 855 753 22 30
From the UK: +44 (0) 20 336 453 74

The presentation will also be webcast and can be accessed from the following web address:
https://edge.media-server.com/m6/p/95yxnc6z

Host: Viktor Drvota, CEO.

For further information, please contact:

Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com

Christian Tange, CFO, Karolinska Development AB
Phone: +46 73 712 14 30, e-mail: christian.tange@karolinskadevelopment.com

TO THE EDITORS

About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.

Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.

Karolinska Development has established a portfolio of ten companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.

For more information, please visit www.karolinskadevelopment.com

This information is information that Karolinska Development AB (publ) (Nasdaq Stockholm: KDEV) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of Viktor Drvota, at 08:00 am CET on 31 October 2017.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Karolinska Development AB (publ) via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Arcoma presenterar på Redeye Life Science Day den 21:a november16.11.2018 12:53Pressmeddelande

16 November Den 21 november presenterar Jesper Söderqvist, VD på Arcoma, den senaste utvecklingen i Arcoma på Haymarket by Scandic i Stockholm. Presentationen "Arcoma, ett tillväxtbolag i en växande marknad" hålls klockan 13:00 och kan följas i livesändning på redeye.se/live/lsday-2018. Presentationen kommer även i efterhand att finnas tillgänglig på www.redeye.se/live/ls-day-2018 samt på Bolagets sida i Redeye Universe (redeye.se/company/Arcoma) Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum